COMPOSITION FOR ANTICANCER TREATMENT CONTAINING NK-CELLS AND FUSION PROTEIN WHICH CONTAINS IL-2 PROTEIN AND CD80 PROTEIN Russian patent published in 2024 - IPC A61K38/17 A61K38/20 A61K35/17 C12N5/783 C07K14/55 C07K14/705 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, specifically to an agent containing NK cells as active ingredients and a fusion protein which contains IL-2 protein and CD80 protein and can be used in medicine for cancer immunotherapy. Disclosed is a method of treating cancer, involving administering a fused protein dimer containing the amino acid sequence SEQ ID NO: 9, 26, 28 or 30, in combination with natural killer cells, and a pharmaceutical composition of said dimer of fused protein and natural killer cells.

EFFECT: inventions provide significant inhibition of tumour growth in comparison with groups treated with natural killer cells or fusion protein separately.

3 cl, 35 dwg, 10 tbl, 14 ex